Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
 Your new post is loading...
Scoop.it!
From
stwem
If one takes a long view of the history of technological innovation in business, a pattern can be perceived. How could one use those patterns to initate a series of tactics to create an innovative attitude and actual developments? 10 Hinta by Andrew Spong 
No comment yet.
Sign up to comment
Scoop.it!
People love to help each other online and they are turning to branded websites to get information so why the focus on social media when there is communities...
Scoop.it!
Though pharma is not allowed in Europe to (digitally) market to consumers, marketeers might benefit from fenerla insights into profiles of consumers interested in pharma ads in the States. These insights may give them information to use to inform doctors. However, by listening and reading patients' conversations on line in Europe itself, they might learn the best! By broadening targeting opportunities pharma marketers can increase the reach of their direct to consumer online ads.
Scoop.it!
The pharmaceutical giants look remarkably similar to the IBM of the late 80′s and early 90′s.
For those of us who remember the IBM of that era, this is bad news.
They can continue the path of the railroad industry early in the 20th century. Alternatively, they can look to the path IBM took when its future prospects were grim.
Remarkably, IBM demonstrated how it’s possible for a large company to shift from a product-centric culture to a customer and service centered company.
The writing is on the wall for pharma companies: they will succeed or fail based not on how many drugs they sell, but on how well their offerings improve health outcomes.
Scoop.it!
The industry does have regulations that cover digital marketing, but much rests on interpretation - PMLiVE... Via Angel Gonzalez
Scoop.it!
Drug pipelines improving after years in doldrums: - According to data from Thomson Reuters, drug industry productivity is improving after years of research disappointment, as drugmakers shift their focus from blockbuster drugs to making medicines for rare diseases, as reported Tuesday on Yahoo!News. -"There has clearly been a downward trend in R&D efficiency in the past but what we are seeing now are some indicators that may be reversing," said Chris McKenna, vice-president for professional services at Thomson Reuters Life Sciences. "New molecular entity output is improving and the number of projects going into clinical development is declining, which indicates the industry is moving away from a numbers game and is focusing on better-quality candidates ... we probably need a couple more years to see if it is a sustained pattern," McKenna added.
Scoop.it!
Pharmaceuticals Executive Survey: KPMG's results from 2011 Pharmaceutical Pulse survey: - M&A activity is expected to heat up in the sector over the next two years; - Pharmaceutical executives are not expecting a full economic recovery for a few years; - Growth in foreign markets is seen as an increasing area of importance; - Headcount is down significantly from a year ago; - The majority of pharmaceutical industry executives say that U.S. healthcare reform legislation is not addressing the real challenges for U.S. healthcare (63 percent)..
Investment priorities were to be seen in, a.o.: - Acq of business: 40%; - New products or services: 38%; - Business model transformation: 19%..
Industry challenges Looking forward, pharmaceutical executives view external factors with much greater concern than internal factors. A large majority of executives (76 percent) admitted being concerned about the economy, competition, and the impact of regulatory changes compared to their ability to compete or whether they have the right strategic direction internally (24 percent). In addition, it is not surprising that sector executives identified regulatory and legislative pressures (60 percent) as the most significant barrier to growth over the next year, followed by pricing pressures (55 percent).
Original data at KPMG's site - not rewritten text by review sites (stating it was data from 2012!)..
Scoop.it!
It was only a matter of time before healthcare providers would start prescribing mHealth apps as soon as they proved to be as or more effective than prescription drugs. Smart pharma will become players, not just spectators in industry disruption.. It seems that a day doesn’t go by where I don’t hear about some pharma sponsored “app challenge.”
Scoop.it!
IBM's recommendations to pharma include:
* Provide more information on drugs, medication and supporting services to a targeted audience * Provide information about research on new drugs to the general community * Educate the community about health issues/awareness and treatment * Deepen the connection with groups of patients and healthcare professionals through unbranded presences * Provide information on drug recalls more rapidly and to a wider audience than currently is the case
Scoop.it!
Medical devices that are part app, part consumer gadget are spurring changes. It also suits the pharmaceutical industry's shift toward a more diversified offering featuring not just drugs and biologics but also diagnostics, devices and services, bundled together to give their therapies an edge with increasingly powerful and tightfisted payers.. “Doctor-patient facetime is where most pharmaceutical products focus their marketing efforts,” says HAVAS Health chief digital officer Larry Mickelberg. “Now they've got to think about the in-between time, and that's where innovation is going to happen. It's a characteristic difference between the old healthcare mindset and the way things are moving, and that means rather than periodic exchanges of information between doctor and patient during scheduled visits, all parties can now consult and exchange information in a continuum across multiple channels.”
Scoop.it!
Why We Work in Healthcare By Bruce Grant In 1948, the year I was born,...
Scoop.it!
Working Life: Jane GriffithsInPharmI joined Janssen, the pharmaceutical division of Johnson & Johnson, as a sales representative after completing my PhD at the University of Aberystwyth in 1982. ...Now we follow the product in the real patient environment. Health literacy, adherence and patient responsibility are essential to increasing therapeutic effectiveness. Luckily, in today’s world, the patient is an informed participant, and this is also changing the dynamic of healthcare. Rather than simply providing safe and efficacious products, we need to provide healthcare and health services that go beyond the disease, supporting the quality of life of the whole person....
Scoop.it!
Pharma rocks many Twitter handles for many reasons The Twittersphere is lousy with pharma feeds. Count them up, as Eye on FDA recently did, and 44 drugmakers operate 200 Twitteraccounts, and the number appears to be growing as pharma companies raise their online profiles and tailor their social media strategies. Yet there are gray areas around how to operate in the realm of the social web, calling for careful stewardship of Twitter accounts and Facebookpages, where the possibility exists for companies to have their products and profiles dragged through the digital mud...
Scoop.it!
Visit the My Cancer Circle support group for stories, message boards and other resources for cancer patients, caregivers and family members.
Scoop.it!
In this special report, eyeforpharma examines the ways pharma can use social media to engage patients, customers, and payers
Scoop.it!
Pharmaceutical Industry | NEWS | | Lilly launches oncology trial app for healthcare professionals - Aims to increase patient participation in cancer trials | PMLiVE...
Scoop.it!
A recent Cutting Edge Information study examining the marketing resource allocations of 15 pharma brands to show how pharma marketing strategies are evolving to stay inline with physician and patient demand for digital information suggests digital marketing spend continues to rise within pharma brand teams.
Communiqué reports:
'The study considered three critical phases of drug commercialisation: phase III to regulatory approval, approval to launch, and launch to six-months post-launch. On average the 15 pharmaceutical brands spent $150,000 on digital marketing per molecule during the phase IIIA development. This figure then tripled between regulatory approval and immediately after the launch.'
Scoop.it!
So what does all this mean to pharma? Based on the meager existing pharma usage of Pinterest, it's very hard to say. Like all social media, the tool is designed to facilitate conversations between people, a conversation that ...
Scoop.it!
It’s time for another round-up of interesting players in the social business space.
Scoop.it!
In the grand experiment that is healthcare social media, there have certainly been some hits and misses. The lack of clarity around the ROI in social media for pharmaceutical companies (or anywhere, really) in combination with a lack of comprehensive guidance from the U.S. Food and Drug Administration makes it ground on which drug companies have for the most part have tip-toed. But among removed Facebook pages and shuttered YouTube accounts, a few companies have taken risks and shown us what value social media can have for pharmas.
Below are four examples of campaigns that have helped pushed pharmaceutical social media forward:
1. Boehringer Ingelheim – Drive4COPD 2. Sanofi Diabetes US 3. Novo Nordisk – Race with Insulin 4. AstraZeneca – Prescription assistance program Via Parag Vora, Lionel Reichardt / le Pharmageek
Scoop.it!
Companies appear to be trying to do what social media does – target select audiences with specific messaging – or as I like to call it “niche-casting”. What are the areas of breakdown? Geography – No surprises here, much of ...
Scoop.it!
Pharma feeds multiply on TwitterFiercePharmaAbout half of the companies have just one news stream on the social-media network. Twenty-three have more than one, and one company operates as many as 21, Eye on FDA's census found.
Scoop.it!
Pharmaceutical Industry | NEWS | | Enormous value in 'appropriate use' of healthcare data - Report says governments, organisations and individuals could benefit from effective 'trade rules' for data | PMLiVE...
Scoop.it!
As budgets are cut and many of the pharmaceutical industry's most lucrative drugs come off patent, will the drug industry be able to make the medicines for the future?
Scoop.it!
Canada has approved the world’s first stem cell drug, marking an historic day for the burgeoning therapy.
Osiris' Prochymal is now approved in Canada in children with graft versus host disease (GvHD), a potentially deadly complication from a bone marrow transplant, when newly implanted cells attack the patient’s body.
Prochymal is made up of bone marrow stem cells derived from an adult donor and is designed to control inflammation, promote tissue regeneration and prevent scar formation – GvHD affects around 3,500 to 4,000 worldwide.
“Today, Osiris turns the promise of stem cell research into reality, delivering on decades of medical and scientific research,” said Peter Friedli, chairman and co-founder of Osiris.
“It took 20 years of hard work and perseverance and I want to personally thank everyone involved for their dedication to this important mission.” The approval is based on recent trial results that showed statistically significant improvement in survival in patients taking Prochymal, when compared with a historical control population of children with refractory GvHD.
Andrew Daly, principal investigator in the Phase III programme for Prochymal, said: “I am very proud of the leadership role Canada has taken in advancing stem cell therapy and particularly gratified that this historic decision benefits children who would otherwise have little hope.
“As a result of Health Canada’s comprehensive review, physicians now have an off-the-shelf stem cell therapy in their arsenal to fight GvHD. “Much like the introduction of antibiotics in the late 1920s, with stem cells we have now officially taken the first step into this new paradigm of medicine.” It has not been an easy road for the firm - in 2009, two late-stage clinical trials failed to show the drug was more effective overall than a placebo in treating the disease.
But it did show promise in certain subgroups of patients, and the firm later re-analysed its data to confirm that its drug could increase survival in this patient population.
The Canadian regulators have told Osiris that it must carry out further testing on the drug after it reaches the market.
Osiris, which is based in Columbia, Maryland, plans to submit its drug with the FDA by the end of this year, including its newly analysed information.
Boost for stem cell research
Dozens of adult stem cell therapies are currently moving through clinical trials, and Canada’s approval of Prochymal will be a boost to many working in the field.
But the use of stem cells remains controversial, as some are derived from the cells of embryos. However, stem cells derived from adult tissue such as fat or bone marrow – such as with Osiris’ drug - can get around these ethical concerns.
Osiris signed a pact potentially worth around $1.4 billion with Genzyme in 2008 to develop Prochymal and another stem cell drug, Chondrogen, for osteoarthritis.
But in February Genzyme, now a part of Sanofi, said it had discontinued its project with Prochymal for GvHD. Via Thibaud Guymard
|
